Overview

Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)

Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This survey is being conducted to assess the safety and efficacy of niacin (+) laropiprant (TREDAPTIVE) in usual practice in Korea according to the new product re-examination regulations of the Korean Food and Drug Administration.
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Niacin
Niacinamide
Nicotinic Acids